What is Acticor Biotech?
Acticor Biotech is a biopharmaceutical firm dedicated to pioneering novel therapies for acute thrombotic conditions, with a particular emphasis on acute ischemic stroke. Its flagship product, Glenzocimab, is a first-in-class drug candidate designed for emergency cardiovascular interventions. Originating as a spin-off from the French National Institute of Health and Medical Research (INSERM), Acticor Biotech is strategically positioned to address unmet medical needs within the cardiovascular disease landscape, targeting healthcare providers and institutions globally.
How much funding has Acticor Biotech raised?
Acticor Biotech has raised a total of $12.8M across 4 funding rounds:
Private Equity
$1.5M
Private Equity
$1.6M
Series A
$2M
Series B
$7.6M
Private Equity (2016): $1.5M, investors not publicly disclosed
Private Equity (2017): $1.6M led by Karista
Series A (2018): $2.1M supported by Anaxago, Primer Capital, and Karista
Series B (2019): $7.6M featuring Karista, Anaxago, Newton BioCapital, and Go Capital
Key Investors in Acticor Biotech
Karista
Karista is an independent venture capital firm with over 20 years of experience backing European companies in Digital, Technology, and Healthcare. They focus on providing early-stage support to founders and entrepreneurs.
Anaxago
Anaxago is an investment platform that supports companies in their funding rounds. Their focus often includes innovative sectors like biotech.
Go Capital
Go Capital is a venture capital firm that invests in French technology companies. They provide financial and strategic support to help businesses grow and innovate.
What's next for Acticor Biotech?
The recent major strategic investment signifies a pivotal moment for Acticor Biotech, likely enabling the company to advance its clinical development pipeline and potentially scale its operations. This infusion of capital is crucial for navigating the complex regulatory pathways and market entry strategies inherent in the biopharmaceutical sector. The company's focus on thrombotic diseases, a significant area of unmet medical need, positions it for potential future growth and impact on patient outcomes. Further strategic partnerships or funding rounds may be anticipated as Glenzocimab progresses through late-stage clinical trials.
See full Acticor Biotech company page
